Clinical Trial Detail

NCT ID NCT03066661
Title Expanded Access to Entrectinib for Cancers With NTRK1/2/3, ROS1, or ALK Gene Fusions
Recruitment No longer available
Gender both
Phase Expanded access
Variant Requirements yes
Sponsors Ignyta, Inc.
Indications

Advanced Solid Tumor

Therapies

Entrectinib

Age Groups: adult child senior

Additional content available in CKB BOOST